Conventional tumor markers lack diagnostic accuracy; recent advancements in next-generation sequencing have identified actionable mutations, such as FGFR2 fusions and IDH1/2 mutations, enabling targeted therapies that improve survival. The gene discussed is IDH1; the disease is neoplasm.